Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liver.
The capsid protein synthesis in targeted tissues resulting from residual contaminating replication-competent adeno-associated virus particles (rcAAV) remains a concern for hazardous immune responses that shut down the factor IX expression in the hemophilia B clinical trial. To systematically reduce/eliminate the effects of potential contaminating rcAAV particles, we designed a novel adeno-associated virus (AAV) helper (pH22mir) with a microRNA binding cassette containing multiple copies of liver-specific (hsa-mir-122) and hematopoietic-specific (has-mir-142-3p) sequences to specifically control cap gene expression. In 293 cells, the rep and cap gene from pH22mir functioned similarly to that of conventional helper pH22. The vector yields and compositions from pH22mir and pH22 were indistinguishable. The performance of vector produced in this new system was comparable to that of similar vectors produced by conventional methods. In the human hepatic cell line, the capsid expression was reduced significantly from cap-mir cassette driven by a cytomegalovirus promoter. In the liver, 99.9% of capsid expression could be suppressed and no cap expression could be detected by western blot. In summary, we demonstrated a new concept in reducing de novo capsid synthesis in the targeted tissue. This strategy may not only help AAV vectors in controlling undesirable capsid gene expression, but can also be adopted for lentiviral or adenoviral vector production.
Sol Sherry Thrombosis Research Center, Department of Microbiology and Immunology, Temple University, Philadelphia, PA 19140, USA.
Hui
H
Lu
Guang
G
Qu
Xiao
X
Yang
Ruian
R
Xu
Weidong
W
Xiao
D000704:Analysis of Variance; D000818:Animals; D015153:Blotting, Western; D036022:Capsid Proteins / Q000096:biosynthesis* / Q000378:metabolism; D002460:Cell Line; D000229:Dependovirus / Q000502:physiology*; D004797:Enzyme-Linked Immunosorbent Assay; D005697:Galactosides; D015967:Gene Expression Regulation, Viral / Q000187:drug effects*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000235:genetics; D002836:Hemophilia B / Q000235:genetics / Q000628:therapy* / Q000821:virology; D006801:Humans; D007211:Indoles; D051379:Mice; D008810:Mice, Inbred C57BL; D035683:MicroRNAs / Q000494:pharmacology*; D009841:Oligonucleotides / Q000235:genetics; D014162:Transfection
D036022:Capsid Proteins; D005697:Galactosides; D007211:Indoles; C531907:MIRN122 microRNA, human; C555159:MIRN142 microRNA, human; D035683:MicroRNAs; D009841:Oligonucleotides; C044888:5-bromo-4-chloro-3-indolyl beta-galactoside
J Virol. 2002 Feb;76(4):1904-13
11799185
Mol Ther. 2009 Mar;17(3):417-24
19127250
Nat Med. 1997 Nov;3(11):1295-7
9359708
N Engl J Med. 2010 Oct 7;363(15):1429-37
20925545
J Virol. 2009 Jul;83(13):6817-24
19369348
Hum Gene Ther. 2008 Jun;19(6):648-54
18500941
Gene Ther. 2009 Mar;16(3):311-9
19052631
J Clin Invest. 2009 Jun;119(6):1688-95
19436115
Hum Gene Ther. 2009 Aug;20(8):796-806
19569968
Mol Ther. 2000 Oct;2(4):394-403
11020356
Proc Natl Acad Sci U S A. 1997 May 27;94(11):5804-9
9159155
Mol Ther. 2008 May;16(5):924-30
18388928
Hum Gene Ther. 2009 Aug;20(8):807-17
19604040
Proc Natl Acad Sci U S A. 2009 Jun 30;106(26):10770-4
19541644
Nat Med. 2006 Mar;12(3):342-7
16474400
Mol Ther. 2005 Feb;11(2):320-6
15668144
J Virol. 1997 Sep;71(9):6816-22
9261406
Curr Opin Drug Discov Devel. 2003 Mar;6(2):174-8
12669452
J Immunol. 2009 May 15;182(10):6051-60
19414756
Lancet. 2009 Nov 7;374(9701):1597-605
19854499
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16363-8
19706466
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D109-11
14681370
Mol Ther. 2009 Jan;17(1):144-52
18941440
Gene Ther. 2009 Dec;16(12):1416-28
19727141
J Virol. 1998 Jul;72(7):5472-80
9621003
J Gene Med. 2009 Dec;11(12):1095-102
19777488
Mol Ther. 2008 Dec;16(12):1960-7
18827805